Hypophosphatemia is recognized most often in critically-ill patients, decompensated diabetics, alcoholics or other malnourished persons, and acute infectious or pulmonary disorders.
A decrease in serum phosphate should be distinguished from a decrease in total body storage of phosphate.
Hypophosphatemia may be transient and reflect intracellular shift with minimal clinical consequences.
Most symptoms of acute hyperphosphatemia are due to secondary hypocalcemia.
The significant level of hyperphosphatemia in adults is 5 mg/dL.
Laparoscopic sleeve gastrectomy (SG) appears to be effective in Asians, with early weight loss correlating with midterm weight maintenance and remission of obesity-related comorbidities 1 year after the surgery, according to a study.
The novel, G-protein coupled receptor 119 (GPR119) agonist DS-8500a demonstrated dose-dependent glucose-lowering effects and favourable improvements in lipid parameters that extended up to 12 weeks in Japanese patients with type 2 diabetes mellitus (T2D), according to data presented at EASD 2017.
The incidence of cardiovascular (CV) events at 5 years was similar when adding sulphonylureas or pioglitazone to metformin in patients with type 2 diabetes (T2D) inadequately controlled with metformin alone, according to a head-to-head comparison in the TOSCA.IT* trial.
The American Diabetes Association’s (ADA) President Desmond Schatz challenged the scientific community to transform diabetes from an invisible disease to a highly visible crisis. “Diabetes is an epidemic spiralling out of control across this country and around the world, yet it remains largely invisible,” he said, speaking at the 76th Scientific Sessions of ADA in New Orleans, Louisiana, US.